Cellebration’s science partner, the Global Institute of Stem Cell Therapy and Research (GIOSTAR) has granted Cellebration worldwide rights to market its Food & Drug Administration (FDA) approved Covid 19 stem cell treatment.

GIOSTAR was granted this approval under the FDA’s compassionate use program.

Preliminary results using the treatment have proven encouraging.

Cellebration is closely monitoring the global effects of the Covid 19 pandemic and is actively working with GIOSTAR to create a marketing strategy that is in compliance with the requirements of the compassionate use program while leveraging Cellebration’s ability to offer lifestyle, regeneration, anti-aging, and autoimmune disease treatments to address other patient concerns.